These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20414010)

  • 1. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
    Kodama Y; Kami M
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract]   [Full Text] [Related]  

  • 4. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
    Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K
    Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indian patients go to court over cancer drug.
    Murdur G
    BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889
    [No Abstract]   [Full Text] [Related]  

  • 10. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.
    Weisberg E; Griffin JD
    Drug Resist Updat; 2001 Feb; 4(1):22-8. PubMed ID: 11512149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 14. Do affluent societies have the only options for the best therapy?
    Gajewski JL; Robinson P
    Leukemia; 2007 Mar; 21(3):387-8. PubMed ID: 17311066
    [No Abstract]   [Full Text] [Related]  

  • 15. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N; Bossone G; Della Longa G; Di Cocco B
    Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate for chronic myeloid leukemia: what do we really know?
    Husereau D
    Issues Emerg Health Technol; 2002 Dec; (42):1-4. PubMed ID: 12492100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
    Nadav L; Eldor A
    Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleevec approved for first-line treatment of CML.
    FDA Consum; 2003; 37(2):5. PubMed ID: 12715753
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Gordois A; Scuffham P; Warren E; Ward S
    Br J Cancer; 2003 Aug; 89(4):634-40. PubMed ID: 12915870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.